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Huntington disease (HD) is a neurodegenerative disorder
caused by an expansion of a polyglutamine (polyQ) domain in
the N-terminal region of huntingtin (htt). PolyQ expansion
above 35–40 results in disease associated with htt aggregation
into inclusion bodies. It has been hypothesized that expanded
polyQ domains adopt multiple potentially toxic conformations
that belong to different aggregation pathways. Here, we used
atomic force microscopy to analyze the effect of a panel of anti-
htt antibodies (MW1–MW5, MW7, MW8, and 3B5H10) on
aggregate formation and the stability of a mutant htt-exon1
fragment. Two antibodies, MW7 (polyproline-specific) and
3B5H10 (polyQ-specific), completely inhibited fibril formation
and disaggregated preformed fibrils, whereas other polyQ-spe-
cific antibodies hadwidely varying effects on aggregation. These
results suggest that expanded polyQ domains adopt multiple
conformations in solution that can be readily distinguished by
monoclonal antibodies, which has important implications for
understanding the structural basis for polyQ toxicity and the
development of intrabody-based therapeutics for HD.
Huntington disease (HD)5 is a fatal neurodegenerative disor-
der that is caused by an expansion of a polyglutamine (polyQ)
domain in the protein huntingtin (htt), which leads to its aggre-
gation into fibrils (1). HD is part of a growing group of diseases
that are classified as “conformational diseases,” which include
Alzheimer disease (AD), Parkinson disease (PD), the prion
encephalopathies, and many more (2–4). The length of polyQ
expansion in HD is tightly correlated with disease onset, and a
critical threshold of 35–40 glutamine residues is required for
disease manifestation (5). Biochemical and electron micro-
scopic studies with htt fragments demonstrated that expanded
polyQ repeats (39) form detergent-insoluble aggregates that
share characteristics with amyloid fibrils (6–8), and the forma-
tion of amyloid-like fibrils by polyQ was confirmed by studies
with synthetic polyQ peptides (9). Collectively, these studies
demonstrated a correlation between polyQ length and the
kinetics of aggregation. This phenomenon has been recapitu-
lated in cell-culturemodels that express htt fragments (10–12).
Although it is clear that proteins with expanded polyQ repeats
assemble into fibrils in vitro, recent studies have reported that
htt fragments can also assemble into spherical and annular oli-
gomeric structures (13–16) similar to those formed by A and
-synuclein, which are implicated in AD and PD, respectively.
While the major hallmark of HD is the formation of intranu-
clear and cytoplasmic inclusion bodies of aggregated htt (17),
the role of these structures in the etiology of HD remains con-
troversial. For instance, the onset of symptoms in a transgenic
mousemodel of HD follows the appearance of inclusion bodies
(18), while other studies indicate that inclusion body formation
may protect against toxicity by sequestering diffuse, soluble
forms of htt (10, 19, 20). Based on the direct correlation
between polyQ length, htt aggregation propensity, and toxicity
(6), it has been hypothesized that the aggregation of htt may
mediate neurodegeneration in HD. However, there is no clear
consensus on the aggregate form(s) that underlie toxicity, and
there likely exist bioactive, oligomeric aggregates undetectable
by traditional biochemical and electron microscopic ap-
proaches whose formation precedes disease symptoms.
Although identification of the one or more toxic species of htt
that trigger neurodegeneration in HD remains elusive, such
species might exist in a diffuse, mobile fraction rather than in
inclusion bodies (19). A thioredoxin-polyQ fusion protein was
recently reported to exhibit toxicity in ameta-stable,-sheet-rich,
monomeric conformation (21), suggesting that polyQ can adopt
multiple monomeric conformations, only some of which may be
toxic. Consistent with such a scenario, molecular dynamic simu-
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lations and fluorescence correlation spectroscopy experiments
with synthetic polyQ peptides indicate that polyQ domains can
adopt a heterogeneous collection of collapsed conformations that
are in equilibrium before aggregation (22–25).
Although biochemical, biophysical, and computational
approaches have yielded insight into the structures formed by
polyQ in vitro, whether such structures form in vivo remains
largely unknown. Indeed, determining the conformational state
of any misfolded/aggregated protein in situ and/or in vivo
remains a major technical challenge.
Toward this goal, antibodies have been explored as a poten-
tially powerful tool for detecting specific conformations ormul-
timeric states of aggregated proteins in situ. Antibodies specific
for amyloid fibrils often do not react with natively folded glob-
ular proteins fromwhich they are derived, suggesting that such
antibodies recognize a conformational epitope (26, 27). Several
antibodies display conformation-dependent interactions with
amyloids, aggregation intermediates, or natively folded precur-
sor proteins. For example, there are antibodies specific for
paired helical filaments of Tau (28–31), of aggregated forms of
A ranging from dimers to fibrils (32–34), and of native (35) or
disease-related (36) forms of the prion protein. Antibodies have
also been developed that are specific for common structural
motifs associated with amyloid diseases, such as oligomers (37)
and fibrils (38), independent of the peptide sequence of the
amyloid forming protein from which they are derived, suggest-
ing the potential for a common mechanism of aggregation and
toxicity for these diseases.
With regard to htt, several antibodies (MW1, MW2, MW3,
MW4, MW5, IC2, and IF8), which are specific for polyQ
repeats, stainWestern blots of htt with expanded polyQ repeats
muchmore strongly thanhttwith normal polyQ length (39, 40),
suggesting that these antibodies may recognize abnormal
polyQ conformations. Furthermore, these polyQ-specific anti-
bodies have distinct staining patterns in immunohistochemical
studies of brain tissue sections (39). In one study, the affinity
and stoichiometry ofMW1binding to htt increasedwith polyQ
length, suggesting a “linear lattice” model for polyQ (41). This
model is supported by a crystal structure of polyQ bound to
MW1, which showed that polyQ can adopt an extended, coil-
like structure (42). However, an independent structural study
showed that the anti-polyQ antibody 3B5H10 binds to a com-
pact -sheet-like structure of polyQ in a monomeric htt frag-
ment.6 These results clearly indicate that polyQ domains can
fold into at least two unique, stable, monomeric conformations
and suggest that the “linear lattice”model is not generally appli-
cable to all polyQ structures.
Not only are antibodies useful for understanding what polyQ
structures exist in situ, especially in the diffuse htt fraction of
neurons, but antibodies and/or intrabodies may also have
potential as therapeutic agents. For example, several studies
showed that intrabodies reduce htt toxicity in cellular models
(44–49). Moreover, one intrabody (C4) slows htt aggregation
and prolongs lifespan in a Drosophila model of HD (50, 51),
while another (mEM48) ameliorates neurological symptoms in
a mouse model of HD (48).
Three of the antibodies examined in this study (MW1,MW2,
and MW7) modulate htt-induced cell death when co-trans-
fected as single-chain variable region fragment antibodies
(scFvs) in 293 cells with htt exon 1 containing an expanded
polyQ domain (46). In these studies MW1 and MW2, which
bind to the polyQ repeat in htt, increased htt-induced toxicity
and aggregation (46). Conversely, MW7, which binds to the
polyproline (polyP) regions adjacent to the polyQ repeat in htt,
decreased its aggregation and toxicity (46). Interestingly, MW7
has also been shown to increase the turnover of mutant htt in
cultured cells and reduce its toxicity in corticostriatal brain
slice explants (49).
Given the difficulty in understanding which specie(s) of htt
exist and mediate pathogenesis in the putative toxic diffuse
fraction of neurons, we sought to rigorously characterize the
conformational specificity of a panel of anti-htt antibodies, the
best in situ probes currently available for distinguishing spe-
cie(s) of htt. We reasoned that if htt can adopt multiple confor-
mations that mediate different aggregation pathways, then
anti-htt antibodies should differentially alter htt aggregation
pathways by stabilizing or sequestering the specific conformers
or aggregates they recognize. We therefore examined the
effects of various antibodies on mutant htt fragment fibril for-
mation and stability by atomic force microscopy (AFM). Our
results are consistentwith the hypothesis thatmonoclonal anti-
bodies recognize distinct conformational epitopes formed by
polyQ in a mutant htt fragment.
EXPERIMENTAL PROCEDURES
Protein Purification—GST-HD53Q fusion proteins were
purified as described (52). Cleavage of the GST moiety by Pre-
Scission Protease (Amersham Biosciences) initiates aggrega-
tion. Fresh, unfrozen GST-HD53Q was used for each experi-
ment. GST-HD53Qwas centrifuged at 20,000 g for 30min at
4 °C to remove any preexisting aggregates before the addition of
the PreScission protease. MW series of antibodies were
obtained as described previously (39). 3B5H10 was purified as
described before (53).
Western Blot Analysis—For Western blotting analysis, puri-
fied GST-HD53Q proteins were incubated at 37 °C with shak-
ing at 1400 rpm. Solutions were sampled at 0, 5, and 20 h after
the addition of PreScission Protease. Proteins and aggregates
were separated by SDS-PAGE and then transferred onto Prot-
ran BA85 nitrocellulose membranes (pore-size  0.45 m,
Whatman) by standard Western transfer techniques. The
membranes were incubated for 1 h at 37 °C with MW1, MW2,
MW3, MW4, MW5, MW7, MW8, or 3B5H10 at a dilution of
1:1000. The membranes were then incubated with horseradish
peroxidase-conjugated rabbit anti-mouse IgG or IgM (Jackson
ImmunoResearch) at a 1:5000 dilution for 1 h at room temper-
ature. The horseradish peroxidase was detected using an ECL
Advance Western blotting Detection System (Amersham Bio-
sciences), and the membranes were exposed to x-ray films.
Neuronal Culture, Transfection, and Immunocytochemistry—
Primary cultures of rat striatal neurons were prepared from
embryos (embryonic days 16–18) and transfected with plas-
6 C. Peters-Libeu, E. Rutenber, J.Miller, Y. Newhouse, P. Krishnan, K. Cheung, E.
Brooks, K. Widjaja, T. Tran, D. Hatters, S. Mitra, M. Arrasate, L. Mosquera, D.
Taylor, K. Weisgraber, and S. Finkbeiner, submitted for publication.
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mids (6–7 days in vitro) as described (10). Neurons were co-
transfected with pGW1-Httex1-Q46 or 97-GFP in a 1:1 molar
ratio, using a total of 1–4 g of DNA in each well of a 24-well
plate. After transfection, neurons were maintained in serum-
free medium. All immunocytochemistry was performed as
described (54). Cy3-conjugated secondary antibodies targeted
to the appropriate primary antibody were acquired from Jack-
son Immunolabs.
Atomic Force Microscopy—For experiments on monomeric
preparations, GST-HD53Q was incubated at 20 M alone or
with anti-htt antibodies (MW1, MW2, MW3, MW4, MW5,
MW7, MW8, or 3B5H10) in a 1:1 ratio of protein to antigen
binding sites in buffer A (50 mM Tris-HCl, pH 7, 150 mMNaCl,
1 mM dithiothreitol). PreScission protease (4 units/100 g of
fusion protein) was added at time zero to initiate GST cleavage
and aggregation. Samples were incubated at 37 °C with shaking
at 1400 rpm for the duration of the experiment. At time 1, 5, 8,
and 24 h after cleavage of the GST, a sample (5 l) of each
incubation solution was deposited onto freshly cleaved mica
(Ted Pella Inc., Redding, CA) and allowed to sit for 1 min. The
substrate was washed with 200 l of ultrapure water and dried
under a gentle steam of air. For experiments on preformed
fibrils, 40M solutions ofHD53Qwere incubated alone for 5–6
h after the removal of the GST tag to allow the formation of
fibrils. Buffer or anti-htt antibodies (MW1, MW2, MW3,
MW4,MW5,MW7,MW8, or 3B5H10) were added so that the
final concentration of HD53Q was 20 M, and the ratio of
HD53Q to anti-htt antigen binding sites was 1:1. These solu-
tions were sampled immediately and 3 h after the addition of
the buffer or anti-htt antibody. Dose dependence studies of
fibril disaggregation by MW7 and 3B5H10 were performed
similarly, except that the ratio of HD53Q to antibody binding
site varied (10:1, 5:1, and 1:1) and solutionswere sampled at 0, 1,
and 3 h after the addition of the antibodies.
Each sample was imaged ex situ using an MFP3D scanning
probe microscope (Asylum Research, Santa Barbara, CA).
Images were taken with silicon cantilevers with nominal spring
constants of 40 newtons (N)/m and resonance frequency of
300 kHz. Typical imaging parameters were: drive amplitude
150–500 kHz with set points of 0.7–0.8 V, scan frequencies of
2–4 Hz, image resolution 512 by 512 points, and scan size of 5
m. All experiments were performed in triplicate.
For in situAFMexperiments tracking individual fibrils, solu-
tions containing preformed fibrils of HD53Q were allowed to
rest on mica until several fibrils were present on the surface.
Then, the substrate was washed with buffer A to remove pro-
teins remaining in solution. The deposited fibrils were either
imaged in clean buffer as a control or in the presence of anti-htt
antibodies (2.5M final concentration). Imageswere takenwith
V-shaped oxide-sharpened silicon nitride cantilevers with a
nominal spring constants of 0.5 N/m. Scan rates were set at 1–2
Hz with cantilever drive frequencies ranging from8–12 kHz.
Statistics—All error bars in quantification of ex situ AFM
experiments (number of fibrils or oligomers perm2) represent
the standard error of at least three independent experiments
and were compared using a t test. All error bars in quantifica-
tion of in situAFM experiments (change in fibril length) repre-
sent the standard error measured from at least eight individual
fibrils and were compared using a t test. Aggregate populations
based on height were compared using a Spearman’s rank cor-
relation performed with GraphPad Prism.
RESULTS
Anti-htt Antibodies Recognize a Variety of SDS-stable Oligo-
meric Species of HD53Q—All experiments in this study, with
the exception of the immunocytochemistry studies described
later, were performed with a mutant htt fragment that
expresses exon 1 with 53Q (HD53Q). HD53Q was purified
from Escherichia coli as a soluble fusion with glutathione
S-transferase (GST) (Fig. 1) (52). After purification, GST-
HD53Q appeared non-aggregated as determined by AFM anal-
ysis and size-exclusion chromatography (data not shown). The
HD53Q fragment contains epitopes specifically recognized by
the panel of eight independent monoclonal anti-htt antibodies
(Fig. 1A) used in this study. MW1, MW2, MW3, MW4, MW5,
and 3B5H10 are specific for the polyQ domain.MW7 is specific
for the polyP domains. MW8 is specific for the last seven resi-
dues of the C terminus of htt exon 1.
Cleavage of a unique peptide sequence between the GST
moiety and HD53Q with a site-specific protease (PreScission
protease) released the HD53Q fragment, initiating aggregation
in a time-dependent manner as reported (7, 15). Western blots
ofHD53Qwere used tomonitor cleavage 0, 5, and 20 h after the
addition of the protease (Fig. 1B). Before proteolytic cleavage
(t  0 h), most antibodies specific for the polyQ domain
detected a prominent band of intact htt-GST fusion protein
that migrated at an apparent molecular mass of53 kDa, and a
less intense band that migrated at an apparent molecular mass
of a dimer of the fusion protein (106 kDa). At later time
points, MW1 and MW3 recognized the intact fusion protein
and a band that migrated at a lower apparent molecular mass
that may represent monomeric HD53Q (40 kDa). MW2 did
not recognize this 40-kDa species after proteolytic cleavage
but did react with a larger, potentially dimeric species (80
kDa) at later time points.MW4,MW5, and 3B5H10 recognized
a40-kDa species and a variety of SDS-stable bands ofHD53Q,
some of which may be fragments of HD53Q. Only antibodies
that were not specific for the polyQ domain (MW7 and MW8)
recognized large aggregated forms of HD53Q that remained in
the wells of the gel, indicating that the polyQ epitopes recog-
nized by these anti-polyQ antibodies are not accessible or
absent in large aggregates. Of the two antibodies that bound the
large aggregated form, onlyMW7 stained the40-kDa species
of HD53Q. These results indicate quite remarkably that six
independent anti-polyQ antibodies (MW1–5 and 3B5H10)
detect a variety of stable polyQ epitopes formed by HD53Q,
even after apparent htt denaturation in SDS. Two antibodies
against regions outside the polyQ stretch of htt exon1 (MW7
and -8) appear to expand the repertoire of recognizable htt
species further.
Anti-htt Antibodies Recognize a Variety of htt Species in Neu-
rons in Situ—To determine if these anti-htt antibodies could
distinguish different htt epitopes in neurons, we applied immu-
nocytochemistry to an established neuronal model (19) in
which primary striatal neurons are transiently transfected with
a mutant htt exon1 fragment fused to enhanced green fluores-
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cent protein (GFP) (Fig. 1C). We compared the GFP signal,
which exhibited fluorescence in a diffuse cytoplasmic localiza-
tion and in inclusion bodies, to that detected by specific anti-
bodies. Consistent with the results with Western blots, only
MW7 and MW8 labeled large htt inclusion bodies based on
co-localization with the GFP signal from htt. MW7 also stained
diffuse htt. PolyQ-specific antibodies did not stain inclusion
bodies; rather, they recognized a diffuse population of htt pro-
teins. All of these results were consistent with Western blots
from Fig. 1B. This diffuse populationmight contain a heteroge-
neous mix of monomeric conformers and soluble, oligomeric
aggregates. TheWestern blot and immunocytochemistry stud-
ies suggest that these antibodies recognized different conform-
ers or oligomeric forms of HD53Q.
Anti-htt Antibodies Modulate htt Aggregation Differentially—
We next used AFM to analyze the effects of anti-htt antibodies
on HD53Q aggregation. Co-incubation experiments were per-
formedwithmonomeric preparations ofHD53Qand each anti-
body. Representative AFM images of aliquots removed from
solutions of HD53Q in the presence and absence of anti-htt
antibodies after 1, 5, 8, and 24 h of incubation are shown in Fig.
2. The concentration of HD53Q in all solutions was 20M, and
the ratio of antigen binding sites on the antibody toHD53Qwas
1:1. In an effort to quantify the effect the anti-htt antibodies on
fibril formation, AFM images from
all incubations were analyzed by
counting the number of fibrils per
m2 (Fig. 3A). For this analysis, the
number of fibrils in theAFM images
for a given sample was divided by
the total area covered by the AFM
images. Fibrils were defined as
objects with a height larger than 5
nm and a length-to-width (aspect)
ratio3.
The AFM images of HD53Q
incubated alone displayed fibril
growth and an increase in fibril
abundance per unit area over the
24-h time course of the experiment
(Figs. 2 and 3A). At 1 h after removal
of GST, only a small number of
fibrils were present, and these
increased in number and grew from
several hundred nanometers to 1
m in length at later time points.
The fibrils were 6–8 nm tall and
12 nm wide (measured at half
height). Fibril formation in solu-
tions of HD53Q co-incubated with
MW1, MW2, or MW4 altered
aggregation similarly (Figs. 2 and
3A). After 1 h of incubation, the
number of fibrils/m2 significantly
increased in the presence of these
antibodies. Despite this early
increase in the number of fibrils,
MW1, MW2, and MW4 all had sig-
nificantly fewer fibrils than the controls at later time points.
Co-incubation of HD53Q with MW8 also resulted in an initial
increase in the number of fibrils formed, with a significant
reduction compared with controls at later time points. How-
ever,MW8 appeared to be the least effective antibody in reduc-
ing fibril formation after 24 h. At early time points, the number
of fibrils formed in the presence of MW3 and MW5 did not
significantly differ from controls (Figs. 2 and 3A). By 24 h of
co-incubation, however, both MW3 and MW5 had signifi-
cantly inhibited HD53Q fibril formation. These results suggest
thatMW1–5may recognize one ormore conformers ofmutant
htt that are required for efficient fibril formation.
Unlike all other antibodies tested, MW7 and 3B5H10 com-
pletely prevented fibril formation of HD53Q over the entire
time course of the experiment (Figs. 2 and 3A). Instead of fibrils,
compact globular structures were observed in co-incubations
of HD53Q with MW7 or 3B5H10. The height of individual
globular structures was analyzed at all time points for HD53Q
with or without MW7 or 3B5H10 (Fig. 3, B–D). Height was
chosen for analysis because it is the most accurately measured
dimension in AFM, and it does not contain artifacts due to the
finite shape and size of the probe tip. Fibrillar structures were
not included in the analysis with HD53Q alone. In incubations
of HD53Q alone, globular oligomers gradually increased in
FIGURE 1. Anti-htt antibodies recognize a variety species of HD53Q in vitro and in situ. A, a schematic
representation of the GST-htt exon 1 fusion protein with 53Q (HD53Q) shows a PreScission protease site
locatedbetweenGSTand thehtt fragment (not drawn to scale) and the locationsof epitopes for the antibodies
that were used in this study. B, Western blots of HD53Q after incubation with protease for varying times,
probedwith antibodies as labeled. The locationofbands representing intactGST-HD53Q fusionprotein at53
kDa is indicated by a green arrow. A band thatmigrated at an apparentmolecularmass of a dimer of the fusion
protein (106 kDa) is indicated by a red arrow. A blue arrow indicated the location of thewells of the gel where
larger HD53Q aggregates are observed. C, primary cultures of rat striatal neurons expressing a GFP-labeled
mutant htt-exon1 fragment with 97Q were analyzed by immunocytochemistry with antibodies as labeled.
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height as a function of time (Figs. 2 and 3B). The oligomers
observed at 1 and 24 h represented distinct populations of
HD53Q aggregates, because the height distributions were no
longer similar based on a Spearman’s rank correlation coeffi-
cient (p  0.37). MW7 and 3B5H10 appeared to stabilize dis-
tinct globular structures, which likely are complexes of anti-
body and HD53Q, with globular structures observed for
co-incubations of HD53QwithMW7 being slightly larger than
those observed with 3B5H10 (compare Fig. 3C with 3D).
Whereas the mean height of HD53Q oligomers observed in
controls at 24 h was 5.3  1.65 nm, globular species observed
from co-incubations of HD53Q with MW7 and 3B5H10 were
4.4 1.76 nm and 2.6 0.74 nm tall, respectively. The height
distributions under each condition
did not change over time based on
Spearman’s rank correlation coeffi-
cient (p 0.001). That is, the size of
globular species formed upon co-in-
cubation of HD53Q with MW7 was
the same at all time points, as was
true for co-incubations of HD53Q
with 3B5H10. This indicated that
globular species observed in these
co-incubations were different from
those formed in incubations of
HD53Q alone. Overall, the quantita-
tive AFM analyses demonstrate that
antibodies specific for the polyQ
domain modulate HD53Q aggrega-
tion differentially and that antibodies
with specificity for other domains of
htt can also alter this process.
We next performed biochemi-
cal experiments to confirm the
AFM results, in which antibodies
were added to monomeric prepa-
rations of GST-HD53Q before ini-
tiating aggregation with protease.
20 M HD53Q solutions were
sampled after 8 h for Western blot
analysis of aggregate formation by
staining with MW8 (supplemental
Fig. S1). Before addition of prote-
ase (t 0 h), no aggregatedHD53Q
was detected. Aggregated HD53Q
was detected in the wells for
HD53Q alone after 8 h of incuba-
tion; however, there appeared to be
fewer aggregates detected for
HD53Q incubated with MW1–
MW5 and MW8. For co-incuba-
tions of HD53Q with MW7 and
3B5H10, no aggregates were de-
tected in the well, confirming the
complete inhibition of aggregate
formation by these antibodies.
Anti-htt Antibodies MW7 and
3B5H10DisassemblehttAggregates—
To test the effects of different antibodies on pre-aggregated
HD53Q, GST was first removed from HD53Q by proteolytic
cleavage, and then HD53Q was incubated for 6–8 h prior to
addition of anti-htt antibodies. The preincubation resulted in a
large population of HD53Q fibrils (time point 0 h in Fig. 4).
After the initial incubation time, aliquots were deposited on
mica, dried, and imaged. Approximately 10–20 fibrils were
observed per 5 m2 by ex situ AFM. These pre-aggregated
HD53Q solutions were divided into several aliquots to which
buffer (for control) or antibodies were added to a final antigen
binding site to HD53Q ratio 1:1, with a final HD53Q concen-
tration of 20 M. Immediately after buffer or antibody were
added, the HD53Q solutions were re-sampled and imaged to
FIGURE 2. Anti-htt antibodiesmodulate htt aggregation differentially. Representative 2m 2mAFM
images of 20MHD53Q incubated in the absence or presence of antibodies as labeled for 1, 5, 8, and 24 h after
cleavage of the GST moiety. The ratio of antigen binding sites to HD53Q was 1:1. For HD53Q alone and with
MW1-MW5 orMW8, fibrillar structures (black arrows) appeared after 1–5 h of incubation. The number of fibrils
increased at 8 and 24 h. However, it appeared that there weremore fibrils for HD53Q alone. For incubations of
HD53QwithMW7 or 3B5H10, no fibrillar structures appeared throughout the 24-h experiment. In incubations
with MW7, globular aggregates (blue arrows) around3.5 nm tall were the dominant species observed at all
time points. For incubation with 3B5H10, smaller globular species (green arrows)2.5 nm tall were present at
all time points. Shown are representative AFM images. Quantification of the number of fibrils perm2 in these
experiments is shown in Fig. 3.
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verify that fibrils were still present
to obtain a time point 0-h measure-
ment (Fig. 4). The solutions were
then incubated for an additional 3 h,
sampled, and imaged (Fig. 4). Pre-
formed fibrils that were treatedwith
buffer, MW1, MW2, MW3, MW4,
MW5, or MW8 appeared to be sta-
ble, as the number of fibrils perm2
was unchanged between 0 and 3 h
(Figs. 4 and 5A). Importantly, the
two anti-htt antibodies that pre-
vented fibril formation (MW7 and
3B5H10) also significantly reduced
the number of preformed fibrils. At
the 1:1 ratio of antigen binding sites
toHD53Q,MW7and 3B5H10 com-
pletely disaggregated preformed
fibrils.
We next evaluated the dose
dependence of HD53Q fibril disag-
gregation by MW7 and 3B5H10
(Fig. 5,B andC). Preformed fibrils of
HD53Q were treated with MW7 or
3B5H10 at an antigen binding site to
HD53Q ratio of 1:10, 1:5, and 1:1.
Controls consisting of preformed
HD53Q fibrils treated with buffer
were also prepared. The final con-
centration of HD53Q was 20 M in
all experiments. These solutions were sampled at 0, 1, and 3 h
after the addition of buffer, MW7, or 3B5H10 and imaged with
AFM. Preformed fibrils present on mica were significantly
reduced at all ratios of antibody:htt, with a clear antibody dose
dependence for the disaggregation.
Tracking the Fates of Individual HD53Q Fibrils Exposed to
Anti-htt Antibodies in Situ—To further explore the stability of
preformed fibrils of HD53Q, we took advantage of the ability of
AFM in solution to track morphological changes of individual
fibrils as a function of time (Fig. 6 and supplemental movies S1
and S2). Preformed HD53Q fibrils were deposited on mica and
imaged continuously. Buffer (control) or anti-htt antibodies
were injected directly into the fluid cell of the AFM. This
allowed for the tracking of the fate of individual fibrils exposed
to different anti-htt antibodies. Fibrils that were treated with
buffer remained stable with no apparent change in length for
over 300min, verifying that the continual scanning of the AFM
probe tip was not sufficient to invoke mechanical disruption of
fibril integrity (supplemental movie S1). Similarly, the majority
of fibrils treated with MW1, MW2, MW3, MW4, MW5, or
MW8did not exhibit largemorphological changes for up to 300
min during continuous imaging (data not shown). Consistent
with the co-incubation experiments described above, fibrils
exposed to MW7 and 3B5H10 gradually shortened in length
(supplemental movie S2). In the case of MW7, some fibrils
completely disappeared from the surface. We then quantified
the change in length of individual fibrils as a function of time
(Fig. 7, A–I) by subtracting the length at time 0 from the length
FIGURE 3. Quantification over time of HD53Q aggregates in the absence and presence of anti-htt
antibodies. A, the number of fibrils/m2 was calculated from AFM images of HD53Q incubated in the
absence and presence of anti-htt antibodies analyzed at 1, 5, 8, and 24 h of incubation. Compared with
control experiments of HD53Q alone, all of the antibodies significantly reduced the number of fibrils
formed at later time points. However, there was a significant increase in the number of fibrils formed after
1 h for incubations with MW1, MW2, MW4, and MW8. MW7 and 3B5H10 completely inhibited the forma-
tion of fibrils over the time course of the experiments. #, a significant increase (p 0.05) in the number of
fibrils/m2 in comparison to HD53Q alone at the same time point (Student’s t test). * and  denote
significant decreases (*  p  0.01,   p  0.05) in the number of fibrils/m2 in comparison to HD53Q
alone at the same time point (Student’s t test). indicates that no fibrils were observed. The experiment
was replicated six times, and the error bars represent standard error. B–D, height histograms for globular
structures observed in HD53Q alone (B) and withMW7 (C) or 3B5H10 (D) as a function of time. Whereas the
height of HD53Q oligomers gradually increased over time, both MW7 and 3B5H10 stabilized distinct
globular structures that likely represent complexes of HD53Q and antibody. The legend applies to all
panels in the figures.
FIGURE 4. Ex situ AFM analysis indicates that the anti-htt antibodies
MW7and 3B5H10disassemble htt aggregates. Samples of HD53Qwere
incubated for 6–8 h after removal of the GST moiety to form a large pop-
ulation of fibrils. Then, buffer (as control), MW1-MW5, MW7, MW8, or
3B5H10 was added. The ratio of antigen binding sites to HD53Q was 1:1.
The solutions were sampled directly after the addition of buffer/antibod-
ies (t 0 h) and deposited on mica for AFM imaging. Fibrils (black arrows)
were present in all samples at this time. The solutions were incubated for
3 h after the addition of buffer or antibodies and re-sampled. Fibrils (black
arrows) were still present in samples that had been treated with buffer,
MW1-MW5 or MW8. However, fibrils were no longer detected in samples
treated with MW7 or 3B5H10. Treatment with MW7 resulted in a large
population of globular species (blue arrows) that varied greatly in size with
the majority of species ranging in height from 4 to 8 nm. Treatment with
3B5H10 resulted in globular species (green arrows) that were only2.5 nm
tall. Shown are representative 2m 2mAFM images. Quantification of
the number of fibrils per m2 in these experiments is shown in Fig. 5.
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of the fibril at any given time.While the length of fibrils did not
vary as a function of time for HD53Q treated with buffer or
MW1-MW5orMW8 (Fig. 7,A–F andH), all fibrils treatedwith
MW7 or 3B5H10 displayed a negative change in length. The
average rate of change in fibril length was calculated based on
measurements on individual fibrils under all conditions (Fig.
7J). Fibrils exposed to MW7 or 3B5H10 exhibited significant
rates of decreasing contour length compared with control
fibrils, with MW7 disaggregating fibrils at a faster rate than
3B5H10. The other antibodies did not differ significantly from
the buffer control. These results indicate that some, but not all,
anti-htt antibodies can disassemble fibrils in solution.
MW7 and 3B5H10 Disassemble Fibrils by Forming Different
Complexes with htt—Because MW7 and 3B5H10 both pre-
vented fibril formation and destabilized preformed fibrils, we
next compared the height of the globular complexes formed by
htt with the antibodies when the antibodies were added to
monomeric or fibrillar HD53Q (Fig. 8). Globular species
formed after incubation of HD53Q in the absence of antibodies
were predominately 4–5 nm tall with a large number of oli-
gomers taller than 6 nm (Fig. 8A). In contrast, globular species
observed from co-incubations of MW7 or 3B5H10 with mono-
FIGURE 5. Quantification of the number of fibrils/m2 for pre-aggre-
gatedHD53Q treatedwith buffer or anti-htt antibodies. A, the number
of fibrils/m2 was calculated from AFM images of incubations of fibrillar
preparations of HD53Q taken immediately after (t 0 h) and 3 h after the
addition of buffer, MW1-MW5, MW7, MW8, or 3B5H10. The ratio of antigen
binding sites to HD53Qwas 1:1. For comparison, all bars are normalized to
the number of fibrils/m2 at t  0 h for that sample. With the addition of
buffer (control), MW1-MW5, or MW8, there was no change in the number
of fibrils present after 3 h.WithMW7 and 3B5H10, the number of fibrils was
significantly reduced, indicating that these antibodies were able to disas-
semble preformed fibrils. *, p  0.001 (Student’s t test). Error bars repre-
sent standard error. B and C, the dose dependence of fibril disaggregation
was studied by quantitative analysis of AFM images of fibrillar preps of
HD53Q taken immediately after (t 0 h), 1 h, and 3 h after the addition of
B, MW7 or C, 3B5H10. The ratio of antigen binding sites to HD53Qwas 10:1,
5:1, and 1:1. For comparison, all bars are normalized to the number of
fibrils/m2 at t 0 h for that sample. The disaggregation of fibrils by MW7
(B) and 3B5H10 (C) appeared to be dose-dependent. *, p  0.01; **, p 
0.001 (Student’s t test).
FIGURE 6. Monitoring disassembly of single htt aggregates incubated
withMW7or 3B5H10by in situAFM. Samples of HD53Qwere incubated for
6–8 h after removal of the GST moiety to form a large population of fibrils.
These fibrils were deposited on mica and imaged using in situ AFM, which
allows for the tracking of the fate of individual fibrils as a function of time.
These fibrils were imaged in the absence or presence of anti-htt antibodies.
Fibrils appeared to be stable after treatment with buffer, MW1-MW5, orMW8
(location of stable fibrils indicated by black arrows). However, treatment with
MW7or 3B5H10 caused fibrils to disaggregate and/or shorten in length (loca-
tion of disaggregating fibrils indicated by green arrows). Scale bar represents
500 nm and is applicable to all images. See also supplemental movies S1
and S2.
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meric HD53Qwere only 3–4 and 2–3 nm tall, respectively (Fig.
8, B and C). Interestingly, whenMW7 was added to preformed
fibrillar HD53Q and allowed to completely disaggregate the
fibrils (3 h after addition MW7), the resulting oligomeric spe-
ciesweremuch larger than those observed following incubation
of this antibody withmonomeric HD53Q (Fig. 8B). These glob-
ular structures were predominately 5–6 nm tall with a large
number of globular structures taller than 6 nm. Based on a
Spearman’s rank correlation coefficient, this difference in size
was statistically significant, demonstrating that the final size of
the complex formed between MW7 and HD53Q can vary,
depending upon the initial aggregation state of HD53Q. This
result may indicate that MW7 can recognize both monomeric
and aggregated forms of htt, consistent with the immunocyto-
chemical experiments and Western blot analysis (Fig. 1). Sur-
prisingly, the globular structures observed from the complete
disaggregation (3 h after the addition of antibody) of preformed
HD53Q fibrils by 3B5H10 were precisely the same size as those
formedwhen 3B5H10was added tomonomeric HD53Q, based
on Spearman’s rank correlation coefficient. This indicates that,
in contrast toMW7, 3B5H10, which has been previously shown
to bind a monomer of htt,6 forms the same complex with
HD53Q regardless of its initial aggregation state (Fig. 8C). This
suggests that 3B5H10 is incapable of recognizing oligomeric
species of htt. BecauseMW7 apparently recognizes both aggre-
gated and diffuse forms of htt, MW7may be physically disrupt-
ing fibril structure by stabilizing a population of oligomeric
structures. However, as 3B5H10 only recognizes soluble, non-
aggregated forms of htt, it may be tightly binding and seques-
tering a monomeric conformation of htt that is in direct equi-
librium with fibril ends.
DISCUSSION
Expanded polyQ repeats in htt have been postulated to adopt
multiple conformations, but it is unclear which conformations
may exist in neurons and are pathogenic. To study the existence
and effects of different htt conformations in neurons, appropri-
ate conformational probes must be first be established and
characterized. The ability of antibodies to be used in situmakes
them attractive tools to measure htt conformations in neurons
and to ultimately determine their functional significance in HD
pathogenesis. We therefore set out to characterize the range of
htt conformations that can be detected by a panel of anti-htt
antibodies, including many that are specific for expanded
polyQ repeats. Because various htt conformations have been
linked to different aggregation pathways in vitro (15), we rea-
soned that different anti-htt antibodies may have disparate
effects on aggregation if the antibodies are recognizing different
htt conformational epitopes.
In this study we showed that a panel of antibodies (MW1–
MW5 and 3B5H10) that are all specific for polyQ sequences
detected different aggregated species of HD53Q in Western
blots and in cultured neurons. These antibodies also hadwidely
FIGURE 7.Quantification of change in length and rate of change of fibrils
treatedwith anti-htt antibodies.A–I, the change in length (length) of indi-
vidual fibrils imaged in the absence and presence of anti-htt antibodies was
tracked as a function of time as measured by in situ AFM. Fibril length
appeared stable with the addition of buffer (A), MW1-MW5 (B–F), or MW8 (H).
The length of individual fibrils steadily decreased after treatment with MW7
(G) or 3B5H10 (I). J, the average rate of changeof fibril length for fibrils treated
with buffer (as control), MW1-MW5, MW7, MW8, or 3B5H10 was calculated,
showing that only MW7 and 3B5H10 caused a significant change in fibril
length (*, p 0.01 with a Student’s t test).
Antibodies Recognize Distinct Conformers of Huntingtin
21654 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 32•AUGUST 7, 2009
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on August 17, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
varying effects on HD53Q aggregation, and some even disas-
sembled preformed htt fibrils. MW1,MW2, andMW4 initially
increased fibril formation before suppressing it at later time
points. MW3, MW5, and MW8 slowed fibril formation. MW7
(polyP-specific) and 3B5H10 (polyQ-specific) completely pre-
vented the formation of fibrillar structures. These two antibod-
ies also destabilized preformed fibrils despite being specific for
different regions of htt. These results are consistent with the
hypothesis that expanded polyQ repeats can adopt multiple
conformation-specific epitopes that can be easily discriminated
by the immune system.
While compared with controls at later time points, all of the
polyQ-specific antibodies at least partially inhibited the forma-
tion of fibrils. MW1, MW2, and MW4 appeared to initially
boost fibril formation. This initial increase in aggregation is
consistent with previous reports that MW1 and MW2
enhanced aggregation, which was associated with increased
htt-induced toxicity, when they were expressed as scFvs in a
cellular model of HD (46). Among the polyQ-specific antibod-
ies we tested, 3B5H10 appears to recognize a unique polyQ
conformation, because it was the only polyQ-specific antibody
to completely prevent fibril formation and destabilize pre-
formed fibrils. Recent structural studies lend further support to
the notion that polyQ repeats can exist in stable conformations
of different structure. For example, a crystal structure of a
polyQ peptide bound toMW1 showed that polyQ can adopt an
extended, coil-like structure (42). However, an independent
structural study showed that 3B5H10 binds to a compact
-sheet-like structure of polyQ.6We speculate thatMW1bind-
ing to a range of conformations on single-stranded polyQ may
initially catalyze the collapse of polyQ into aggregation-prone
structures, accounting for the early increase in fibril formation
forHD53Q incubatedwithMW1 comparedwithHD53Q incu-
bated in buffer. However, as aggregation starts, the accumula-
tion of MW1 antibody on each HD53Q molecule may eventu-
ally sterically hinder further aggregation, accounting for the late
attenuation in fibril formation for HD53Q incubated with
MW1 compared with HD53Q incubated in buffer. In contrast,
3B5H10’s binding to a compact, double-stranded structure of
polyQmay fully bury the edges of the polyQ conformation that
seeds aggregation, accounting for 3B5H10’s ability to com-
pletely block aggregation. Therefore, our results indicate
unequivocally that polyQ domains can sample at least two
unique monomeric conformations, but the polyQ domains are
likely to adopt other stable ormeta-stable structures aswell. For
example, fluorescence correlation spectroscopy experiments
and molecular dynamics simulations (23) indicate that polyQ
peptides can form a heterogeneous population of collapsed
structures in aqueous solution. In the absence of antibodies, htt
appears to be able to sample multiple conformations; however,
a collapsed conformation appears to be the dominant species as
detected by small-angle x-ray scattering.6
The antibodies MW7 (anti-polyP) and 3B5H10 (anti-polyQ)
both destabilized polyQ fibrils. However, the mechanisms
appear to be different, based on size analysis of the aggregate/
complex after disaggregation. AlthoughMW7 and 3B5H10 are
specific for different regions of htt, there are other notable dif-
ferences between the two antibodies. MW7 is an IgM while
FIGURE 8. Size analysis of aggregate observed with MW7 or 3B5H10
added to monomeric or fibrillar HD53Q. A, HD53Q oligomers (HD53Q
incubated alone) after 5 h of incubation were predominantly 4–5 nm in
height with several as tall as 6–8 nm. B, when MW7 was incubated (added
at t  0 h) with monomeric HD53Q (black diamonds), the height of glob-
ular aggregates formed after 5 h of co-incubation were predominantly
3–4 nm tall, although there was a large portion of taller globular aggre-
gates (shoulder on the right of the histogram). In contrast, when MW7 was
incubated with pre-aggregated fibrillar HD53Q (gray circles), globular
aggregates (conditions where fibrils disaggregated) observed when
imaged 3 h after addition of MW7 were much taller (4 –5 nm) in compari-
son to those formed by adding MW7 to monomeric HD53Q, with a larger
portion of aggregates being 5–10 nm tall. C, when 3B5H10 was incubated
(added at t 0 h) with monomeric HD53Q (black diamonds), the majority
of globular aggregates observed after 5 h co-incubation were 2–3 nm in
height. Similarly, when 3B5H10 was incubated with pre-aggregated fibril-
lar HD53Q (gray circles), globular species (conditions where fibrils disag-
gregated) observed 3 h after the addition of 3B5H10 again were predom-
inantly 2–3 nm tall.
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3B5H10 is an IgG. MW7 recognizes aggregated and diffused
forms of htt by Western blot and immunocytochemistry,
whereas 3B5H10 does not recognize aggregates of htt. MW7
can block fibril formation frommonomeric HD53Q by binding
to a specific conformer, resulting in a stable complex with a
narrow size distribution. However, MW7 can also bind aggre-
gates and may physically bind to fibrils, disrupting their stabil-
ity, and resulting in a different population of oligomeric com-
plexes with a broader size distribution. Although we did not
observe any direct binding ofMW7 to htt fibrils by in situAFM,
this possibility cannot be ruled out because the8-min interval
between images may not be fast enough to capture such an
event. Although 3B5H10 also formed a stable complex with
monomericHD53Q, it did not appear to bind to large htt aggre-
gates observed by Western blot, biochemical, and immunocy-
tochemical methods, suggesting that 3B5H10 disaggregates
fibrils by sequestering monomeric HD53Q and shifting the
equilibrium toward soluble forms of HD53Q.7 This notion is
supported by the finding that 3B5H10 forms stable complexes
of the same size regardless of whether it was added to mono-
meric or fibrillar HD53Q. Our AFM data also suggest that
3B5H10 is unable to bind oligomeric species of htt, consistent
with 3B5H10’s demonstrated conformational specificity for a
compact, double-stranded conformation of monomeric htt.6
Of the polyQ-specific antibodies used in this study, only
MW1 and 3B5H10 are IgG-type antibodies; the rest are IgM.
We attempted to control for this difference by calculating the
ratio of HD53Q to antibody in all experiments based on antigen
binding sites on the respective antibody. Antibody type did not
appear to have a clear impact on htt aggregation. For instance,
co-incubation of MW1 (IgG) or MW2 (IgM) with monomeric
HD53Q resulted in very similar aggregation profiles; whereas,
3B5H10 (IgG) prevented fibril formation. In regards to fibril
destabilization, antibody type did not appear to play a role,
because 3B5H10 reduced the number of fibrils even at a ratio of
five peptides per antigen binding site, which is analogous to the
dilution factor used to control for IgM type antibodies. 3B5H10
was still effective in destabilizing fibrils even at a dilution of
10:1, yet none of the polyQ-specific IgM type antibodies desta-
bilized fibrils. The other IgG-type polyQ-specific antibody,
MW1, did not disaggregate fibrils even at a ratio of 1:1. There-
fore, the effects of these antibodies on htt aggregation and
aggregate stability cannot be simply correlated to their anti-
body type. This notion is further supported by the observations
that MW7 (polyP-specific), which is an IgM type antibody, was
able to completely prevent fibril formation and destabilize pre-
formed fibrils.
The ability of MW7 to prevent fibril formation and destabi-
lize preformed HD53Q fibrils provides additional support for
the importance of the polyP domains in htt aggregation. More
broadly, it also indicates the critical importance of flanking
sequences on polyQ structure and aggregation. Studies on syn-
thetic peptides revealed that the addition of a 10-residue polyP
sequence to the C terminus of a polyQ peptide altered both
aggregation kinetics and conformational properties of the
polyQ tract (56). Flanking polyP sequences can also inhibit the
formation of -sheet structure in polyQ peptides by inducing a
PPII-like helix structure, extending the length of the polyQ
domain necessary to induce fibril formation (57). Flanking
sequences in htt exon1 of various polyQ domain lengths mod-
ulate toxicity in yeast models, not only in cis, but also in trans
during aggregation (58, 59). Interestingly, the proline-rich
regions of htt exon1 reduced polyQ-related toxicity in these
studies (58, 59).
Protein interactions with the polyP sequence in htt may have
a major influence on the conformation of the adjacent polyQ
domain. Other studies have demonstrated that the polyP
domain of htt interacts with vesicle trafficking proteins (i.e.
HIP1, SH3GL3, and dynamin), whichmay lead to sequestration
of these proteins in inclusion bodies (61). By analogy, MW7
binding to the polyP domains of HD53Q may stabilize a con-
formation of the polyP domains that can, in turn, prevent the
necessary conformational changes in the polyQ domain that
lead to fibril formation. Such findings underscore the critical
importance of protein context in polyQ aggregation and aggre-
gate stability. There are currently nine diseases related to polyQ
expansions in proteins that are broadly expressed, and the
nature of the proteins that contain the polyQ domain and their
associated pathologies differ substantially. That is, eachmutant
polyQ protein causes a distinct neurodegenerative disease that
is associated with a different population of affected neurons. It
is likely that the protein context of the expanded polyQ
domains associatedwith each disease, and concomitant protein
interactions that vary due to protein context, could help
explain, at least in part, the striking cell specificity that is
observed in each disease.
Because MW7 and MW8 displayed similar behavior in rec-
ognizing aggregated forms of htt by Western blot analysis and
immunocytochemical studies of a HD neuronal model, it is
interesting that MW7 was much more effective in preventing
htt aggregation from monomers. This provides further evi-
dence that the polyP region plays an important role in htt aggre-
gation compared with the specific motif recognized my MW8.
Further, it appears that binding of an antibody to aggregated
forms of htt is not sufficient to disrupt aggregate stability as
MW8, which recognized aggregated forms of htt, was not able
to disaggregate preformed fibrils.
The AFM studies presented here are consistent with previ-
ous reports that MW7 suppresses aggregation and toxicity
when it is expressed as a scFv in cellular (46, 49) andDrosophila
(60) models of HD. Co-transfection of MW7 with mutant htt
exon 1 in corticostriatal rat brain slices increased the number of
healthy medium spinal neurons (49). Interestingly, expression
of theMW7 scFVpromotes turnover of htt in cellularmodels of
HD (49). These results indicate that the ability of MW7 to pre-
vent htt aggregation and destabilize htt fibrils, observed in this
study, may play a pivotal role in the ability of MW7 to reduce
cellular toxicity in a variety of HD models.
An important finding in the present study is that htt aggre-
gation can be reversed by antibodies. There is a great deal of
interest in the use of antibodies and intrabodies as potential
7 M. Arrasate, J. Miller, E. Brooks, C. Peters-Libeu, J. Legleiter, D. Hatters, J.
Curtis, K. Cheung, P. Krishnana, S. Mitra, K. Widjaja, B. Shaby, Y. Newhouse,
G. Lotz, V. Thulasiramin, F. Sandou, P. J.Muchowski,M. Segal, K.Weisgraber,
and S. Finkbeiner, submitted for publication.
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therapeutic agents to treat HD and other polyQ disorders (44–
47, 50). Our observations point to the potential for preventing
aggregation and also destabilizing pre-existing aggregated
forms of htt. By promoting formation of soluble forms of htt,
antibodies and intrabodies may increase htt turnover, as was
shown with a htt fusion protein system in HEK293 cells
cotransfected with a scFv of the antibody MW7 (49). This ob-
servation is consistent with MW7-promoting soluble forms of
HD53Q when added to monomeric or fibrillar forms of the
protein, as demonstrated here. Such a notion is supported by
mouse models, which demonstrate that continuous expression
of mutant htt is required to maintain inclusion integrity and
disease symptoms (62). However, without clear knowledge of
what constitutes a toxic species or conformation, altering the
aggregation process could also conceivably lead to detrimental
effects. For example, if a particular antibody recognizes a non-
toxic htt conformer, in principle itmight actually shift the equi-
librium of aggregate species in a manner that would increase
the concentration of a toxic conformer(s). Although we show
here that the equilibrium of htt aggregation can be altered in
vitro by antibodies, other exogenous factors, including molec-
ular chaperones, may possess similar activities (15, 43, 55).
Because our panel of anti-polyQ antibodies displayed dra-
matically different properties, we speculate that polyQ
repeats can display a wide variety of conformation-specific
epitopes in vivo and that polyQ misfolding and aggregation
within the context of the htt protein may be a far more com-
plex process than previously imagined. Thus, additional
analyses of which polyQ structures anti-htt antibodies rec-
ognize, whether or not they can be used to track the fate of
specific conformers and/or oligomeric species of htt in vul-
nerable neuronal populations in situ, and the evaluation of
their effects in vivo on disease progression in animal models
of HD are clearly warranted.
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Addendum—Consistent with the data we present here, a recent
study showed that a mutant htt fragment can misfold into distinct
amyloid conformations, and, depending onwhether or not the polyQ
domain was exposed or buried in a -sheet, the amyloids can be
either toxic or nontoxic, respectively (Nekooki-Machida et al. (63)).
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